In tubs, tablets, and grab-and-go packets, electrolytes are having a moment. Whether you hear the ads on podcasts, eye them at the grocery store, or watch influencers mix them into their oversized ...
Chronic migraine patients who used GLP-1 receptor agonists to treat conditions like obesity or diabetes had fewer emergency ...
In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose U.S. headquarters is based in Plainsboro, announced it will significantly ...
Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Navigate today’s economy with helpful tips + enter our $26K ...
Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...
Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.
Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results